Is Ruma Care profitable in 2026?

No revenue or profitability figures are disclosed. Ruma Care is a pre-seed startup that raised $2M, went through Y Combinator's Winter 2026 batch, and launched publicly on January 29, 2026, so it is still in early traction-building mode, not profitability.

Who are Ruma Care's biggest competitors?

Ruma Care's closest rivals are SamaCare, which raised a $17M Series B in 2024 for buy-and-bill drug prior authorization, and Mandolin, which says it raised $40M in 2025 and is live at 700+ clinic locations, versus Ruma's two-state footprint.

Could AI replace Ruma Care's own product?

Yes, this is a live risk. Ruma Care's product is itself an AI automation layer for prior authorization, and infrastructure-level tools like Surescripts Touchless PA reported 22-second median approvals across 76,000+ prescribers in 2025, threatening to commoditize the same workflow.

How much funding has Ruma Care raised?

Ruma Care raised a $2M Pre-Seed round with no publicly disclosed lead investor, according to a funding tracker, and went through Y Combinator's Winter 2026 batch; no Series A or priced valuation has been reported as of mid-2026.

What exactly does Ruma Care do?

Ruma Care automates prior authorization, copay assistance enrollment, and reimbursement tracking for biologic infusion clinics, consolidating work the company says otherwise spans 70+ payer portals, per its Y Combinator company profile.

Ruma Care is a privately held, founder-owned startup backed by Y Combinator's Winter 2026 accelerator program and a $2M Pre-Seed round with no disclosed lead investor as of 2026.

YC Winter 2026 · United States

Ruma Care

Software that automates prior authorization for biologic infusion clinics.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from Oct 2027 · Every call on the record Checkpoint: CMS FHIR Prior Authorization API mandate compliance deadline

The call

Ruma Care is building in a real niche already staffed by better-funded rivals, with a 2027 regulatory deadline that could flatten its edge either way.

Ruma Care helps infusion clinics get insurance approval faster by handling paperwork that traditional pharmacy software doesn't cover well. Two bigger competitors, SamaCare and Mandolin, are already doing this in the same space with way more money and more clinics signed up. A new government rule coming in late 2027 will make the approval process more standardized, which could either level the playing field for Ruma or make it even harder to stand out if the bigger players move faster.

Why

AI pressure: Surescripts Touchless PA. Infrastructure-level automation could handle PA submissions directly, cutting out the need for a layer like Ruma's. Could AI do the core job? Yes, likely.

Bigger players: Mandolin. Mandolin already runs in 700+ clinic locations with $40M raised, competing for the same infusion clinics Ruma is trying to sign. Could a giant copy it? Yes, easily.

What protects it. Deep focus on rheumatology and infusion workflows plus direct provider relationships from 150+ pre-launch conversations and the Stanford symposium.

What would change this call

Ruma Care announces a Series A or discloses a lead investor within 12 months. Would show it can compete on capital with SamaCare and Mandolin.
Ruma Care expands live clinics beyond California and Nevada. Would show geographic traction against Mandolin's 700-location footprint.
CMS finalizes FHIR PA API mandate compliance details ahead of Oct 2027. Would show the submission layer commoditizing, reducing Ruma's differentiation window.

Key numbers

$2M pre-seed raised (2026)
Live in 2 states: CA and NV (2026-02)
Mandolin has 700+ clinic locations vs Ruma's early rollout (2026)

Named risks

SamaCare and Mandolin are far better funded and racing the identical buy-and-bill PA wedge. Severity: high
CMS FHIR PA API mandate effective October 1, 2027 could commoditize the submission layer Ruma automates. Severity: high
No verified data, integration, or lock-in moat; denial-pattern learning claim is unconfirmed by third parties. Severity: medium
Geographic footprint limited to California and Nevada roughly six months after public launch. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
SamaCare	losing to	SamaCare raised $17M Series B in 2024, claims billions processed in medical-benefit drug PA
Mandolin	losing to	Mandolin says it raised $40M in 2025 and is live at 700+ clinic locations vs Ruma's 2 states
Surescripts Touchless PA	contesting	Touchless PA reported 22-second median approvals across 76,000+ prescribers in 2025 pilots
Cohere Health	losing to	Cohere Health reportedly raised over $200M and processed 9M+ authorizations by 2026-03

Questions people ask

Is Ruma Care profitable in 2026?: No revenue or profitability figures are disclosed. Ruma Care is a pre-seed startup that raised $2M, went through Y Combinator's Winter 2026 batch, and launched publicly on January 29, 2026, so it is still in early traction-building mode, not profitability.
Who are Ruma Care's biggest competitors?: Ruma Care's closest rivals are SamaCare, which raised a $17M Series B in 2024 for buy-and-bill drug prior authorization, and Mandolin, which says it raised $40M in 2025 and is live at 700+ clinic locations, versus Ruma's two-state footprint.
Could AI replace Ruma Care's own product?: Yes, this is a live risk. Ruma Care's product is itself an AI automation layer for prior authorization, and infrastructure-level tools like Surescripts Touchless PA reported 22-second median approvals across 76,000+ prescribers in 2025, threatening to commoditize the same workflow.
How much funding has Ruma Care raised?: Ruma Care raised a $2M Pre-Seed round with no publicly disclosed lead investor, according to a funding tracker, and went through Y Combinator's Winter 2026 batch; no Series A or priced valuation has been reported as of mid-2026.
What exactly does Ruma Care do?: Ruma Care automates prior authorization, copay assistance enrollment, and reimbursement tracking for biologic infusion clinics, consolidating work the company says otherwise spans 70+ payer portals, per its Y Combinator company profile.
Who owns Ruma Care?: Ruma Care is a privately held, founder-owned startup backed by Y Combinator's Winter 2026 accelerator program and a $2M Pre-Seed round with no disclosed lead investor as of 2026.

Timeline

2026-06-19Posts Product Engineer job listing, salary range $70K to $220K
2026-05-22Posts Founding Member of Technical Staff role, $160K-$220K plus 0.5-2.0% equity
2026-02-19Co-hosts Biologics Access Symposium with Stanford School of Medicine
2026-02-08Launch coverage cites claimed 50% denial reduction and 20x staff time savings
2026-01-29Public launch on Launch YC with demo video
2025Company founded; later joins Y Combinator Winter 2026 batch

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

CellType OctaPulse The Token Company